BiomX reported the appointment of Paul Sekhri and Alan Moses, M.D., to its Board of Directors. Sekhri brings extensive experience in the pharmaceutical and biotech sectors, including senior leadership positions at Teva, Novartis and Ariad Pharmaceuticals. Dr. Moses brings over 25 years of clinical drug development to the board and has a deep background in the leadership of clinical research, most recently at Novo Nordisk, where he held the position of Global Chief Medical Officer. Sekhri and Dr. Moses will be succeeding Erez Chimovits and Yaron Breski, who are stepping down from their positions as board members. Sekhri is President and Chief Executive Officer of the gene editing company eGenesis. He has served as President and Chief Executive Officer of Lycera Corp., and as Executive Vice President of Business Development and Chief Strategy Officer for Teva Pharmaceuticals. Alan Moses, M.D., was co-founder and co-director of the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT. Dr. Moses served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center in Boston. He was appointed Professor of Medicine at Harvard Medical School. Over the course of 14 years at Novo Nordisk, Dr. Moses served in multiple roles, rising to the position of Senior Vice President and Global Chief Medical Officer.